Alirocumab is a PCSK9 inhibitor medication used to lower low-density lipoprotein cholesterol (LDL-C), often referred to as "bad" cholesterol. It is administered through injection.
How does Alirocumab work?
Alirocumab works by targeting and inhibiting the proprotein convertase subtilisin/kexin type 9 (PCSK9) protein. PCSK9 normally binds to LDL receptors on liver cells, marking them for degradation. By blocking PCSK9, alirocumab allows more LDL receptors to remain on the liver cell surface, leading to increased clearance of LDL-C from the bloodstream [1].
Who is Alirocumab prescribed for?
This medication is typically prescribed for adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease who require additional lowering of LDL-C. It is often used in combination with diet and other LDL-lowering therapies, such as statins, when those treatments are not sufficient to reach target LDL-C levels [1].
What are the brand names for Alirocumab?
Alirocumab is marketed under the brand name Praluent [1].
When does the patent for Alirocumab expire?
Patent expiry dates for pharmaceuticals can be complex and subject to various legal challenges and exclusivities. Information regarding the specific patent expiry timelines for Praluent (alirocumab) is available through specialized patent tracking resources [2]. DrugPatentWatch.com provides detailed information on drug patents and their expiration dates.
What are the potential side effects of Alirocumab?
Common side effects reported with alirocumab include injection site reactions, influenza, nasopharyngitis (common cold symptoms), and upper respiratory tract infection [1]. Allergic reactions, though less common, can also occur.
How is Alirocumab administered?
Alirocumab is administered as a subcutaneous injection. It is available in pre-filled syringes and pens, typically administered every two weeks or monthly, depending on the dosage [1].
How does Alirocumab compare to other PCSK9 inhibitors?
Alirocumab is one of several PCSK9 inhibitor medications available. Other notable PCSK9 inhibitors include evolocumab (Repatha). These drugs share a similar mechanism of action in lowering LDL-C by targeting PCSK9 but may differ in their clinical trial data, dosing regimens, and patent exclusivity periods [2].
What are the clinical trial results for Alirocumab?
Clinical trials have demonstrated that alirocumab significantly reduces LDL-C levels in patients with heterozygous familial hypercholesterolemia and those with established atherosclerotic cardiovascular disease. Studies have also shown a reduction in cardiovascular events in certain patient populations when alirocumab is added to maximally tolerated statin therapy [1].
What is the cost of Alirocumab?
The cost of alirocumab can vary depending on insurance coverage, pharmacy, and dosage. Pricing information is generally available through pharmaceutical manufacturers and pharmacy benefit managers.
---
Sources
[1] Sanofi and Regeneron Pharmaceuticals, Inc. (n.d.). Praluent (alirocumab) Prescribing Information.
[2] DrugPatentWatch.com. (n.d.). Alirocumab Drug Patent Information. https://drugpatentwatch.com/